Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs ING Groep NV (ING) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs ING Groep NV — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while ING Groep NV trades at $32.15 (market cap $92.53B). The key difference: ING Groep NV is far larger — about 2.3× Alnylam Pharmaceuticals, Inc.'s market cap, and ING Groep NV pays a 3.91% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | ING | |
|---|---|---|
Market Cap | $39.89B | $92.53B |
Sector | Health | Financials |
52-Week High | $491.22 | $32.96 |
52-Week Low | $278.09 | $22.45 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 3.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
ING trades at $32.39, down 0.34% today, with a bullish technical outlook supported by moving averages. The company maintains strong profitability with a 27.84% net income margin and has beaten earnings expectations for three consecutive quarters. Recent developments include the launch of a global subscription banking model and a $0.88 dividend payment scheduled for May 2026.
The stock presents a compelling value opportunity with a P/E of 12.99 and strong analyst support (62.5% buy ratings). However, negative operating cash flow trends and exposure to European banking sector volatility represent key risks. Upside potential exists from continued earnings outperformance and strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
